Synergy Pharmaceuticals (NASDAQ:SGYP) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01), MarketWatch Earnings reports. The firm had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.

Shares of SGYP traded down $0.09 during mid-day trading on Friday, hitting $0.36. The company had a trading volume of 9,599,730 shares, compared to its average volume of 7,622,059. Synergy Pharmaceuticals has a 1-year low of $0.35 and a 1-year high of $3.10. The stock has a market capitalization of $114.13 million, a PE ratio of -0.35 and a beta of 2.38.

A number of equities research analysts have recently commented on SGYP shares. BidaskClub downgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 1st. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Synergy Pharmaceuticals in a report on Tuesday, August 7th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a report on Tuesday, August 14th. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Finally, Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. Synergy Pharmaceuticals has an average rating of “Hold” and an average target price of $8.17.

COPYRIGHT VIOLATION WARNING: “Synergy Pharmaceuticals (SGYP) Releases Earnings Results, Misses Expectations By $0.01 EPS” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2018/11/10/synergy-pharmaceuticals-sgyp-releases-earnings-results-misses-expectations-by-0-01-eps.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Further Reading: How Do Tariffs Affect Trade Balances?

Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.